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1. Introduction 
Inflammatory bowel disease (IBD) refers to a chronic inflammation condition of the 
intestinal tract concerning both small and large intestine. The major types of IBD are Crohn’s 
disease (CD) and ulcerative colitis (UC). Both are chronic, relapsing and remitting diseases. 
The etiology of these diseases is quite complicated that involves genetic and environmental 
factors including diets, geographical and socioeconomic status and microbial factors. This 
chapter provides and discusses information about diet, prebiotic and probiotic and their role 
in the development and management of IBD.  
Diet has important role in the development of IBD or protection against IBD. The nutritional 
components contribute in the balance of intestinal microflora either positively or negatively 
depending on the diet itself. Foods have  been previously considered by consumers barely 
in term of taste and immediate nutritional needs. Instead of those two aspects, many 
consumers consider the foods ability to provide specific benefits beyond their nutritional as 
stringent reasons for choosing foods as their daily diet. Thus, functional foods have become 
an important and rapidly growing segment of the food markets, especially for the 
prevention and mangemnt of bowel-related diseases such as IBD. On the other hand, 
Prebiotic components and probiotic bacteria have also been used in the prevention and 
treatment of IBD, and they exhibit proven efficacy in many clinical studies. Prebiotic such as 
inulin and fructooligosaccharides (FOS) are commercially available in the markets, as well 
as probiotic supplemented food such as yogurt and fermented milk. Further information 
regarding this both food products will be discussed later in this chapter. 
This chapter reviews the role of diet and its different elements namely, fibers, proteins, fatty 
acids (saturated and unsaturated fatty acids), and carbohydrates in the development and 
management of inflammatory bowel diseases (IBD). In addition, the chapter will discuss the 
link between life style and nutritional status with the enteric microbiota, and the balance 
between harmful bacteria and the beneficial bacteria  (prebiotic components and probiotic 
bacteria). Moreover, the mechanisms of such relationship between the enteric microbiota 
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and diet will be discussed and explained. And the exact role of prebiotic and probiotic 
bacteria will be discussed thoroughly in the prevention, management and treatment of IBD 
along with the underlying mechanisms. 
2. The healthy and unhealthy diet for intestine 
Foods have a large impact on human digestive tract, particularly for those who have severe 
intestinal disorder such as constipation, inflammatory bowel disease, and colorectal cancer. 
Consumption of water, fiber containing food, prebiotic bacteria, probiotic bacteria, fruits and 
vegetables are thought to be beneficial for intestine, whereas specific red and processed meat 
are inconsistently exert detrimental effect to intestine. Prebotic and probiotic have been 
considered as healthy diet for the intestine. Water is required to keep foods and other substances 
move along more smoothly through the digestive tract as well as to make stools softer and easier 
to pass. In 117 patients with chronic functional constipation, a daily fiber intake of 25 g can 
increase the stools frequency and this effect was significantly enhanced by increasing water 
intake to 1.5-2.0 liters per day (Anti et al., 1998). In contrast, carbonated water improve 
dyspepsia, constipation and gallbladder emptying, however it decreases satiety in patients 
with functional dyspepsia and constipation (Cuomo et al., 2002). In early study, Lepkovsky et 
al. (1957) investigated the gastrointestinal regulation of water in rats fed with or without 
water. Rats fed without water ate less food than rats fed with water. However, the gastric 
contents (49% water) were similar within the both group, indicate close regulation of water in 
the gastric content. The authors suggested that diet without water resulted in decreasing 
appetite and food intake. Schoorlemmer and Evered (2002) revealed that a sensor located in 
the gastrointestinal tract or perhaps in the mesenteric veins, but not the hepatic portal vein or 
the liver mediated the inhibition of feeding during water deprivation. Therefore, water is 
considered as an important component that takes a part in maintaining the intestinal healthy. 
 Dietary fiber is an intrinsic substance of plants that are resistant to enzymatic digestion in 
the gastrointestinal track of human (Schneeman and Tietyen, 1994). It is usually 
differentiated into insoluble fiber (not dissolve in water) and soluble fiber (dissolve in 
water). Chemically, insoluble fiber consists of cellulose, hemicelluloses and lignin, while 
soluble fiber consists of pectin, gum and mucilage. Insoluble fiber enhances the movement 
of material through the digestive track and contributing bulk and moisture to the stool. 
Thus, it can be of benefit to those who suffer with constipation and irregular stools. 
Insoluble fiber is found in food such as whole grains, wheat bran and many vegetables. 
Soluble fiber absorbs water to form a gel-like material and can help lower blood cholesterol 
and glucose levels. Oat, peas, beans, nuts, some fruits and vegetables are good sources of 
soluble fiber. Consuming foods rich in fiber exert numerous benefits such as improved large 
bowel function, slowed digestion and absorption of carbohydrate and fat, and reduced risk 
for certain diseases (Schneeman and Tietyen, 1994). Average intake of dietary fiber in the 
United States is about 5 g/day. However, according to the American Dietetic Association, 
the recommended daily intake of fiber is 25-35 g (Slavin, 2008). Fiber should be increasingly 
consumed in certain time period rather than consumed promptly to achieve value of 
recommended daily intake, as it may cause stomach cramping and gas. In 2001, Bliss et al. 
revealed that dietary fiber may improve fecal incontinence. In their study, patients with 
fecal incontinence who are given dietary fiber as psylium or gum arabic showed 
significantly fewer incontinence stools than with placebo treatment.  
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Consumption of fruits and vegetables are believed to exert many beneficial effects to 
intestine, as they are sources of fiber. Chang et al. (2010) reported that consumption of kiwi 
fruit for 4 weeks be able to shorten colon transit time, increases defecation frequency, and 
improves bowel function in adults diagnosed with constipation. In another study with eight 
healthy volunteers, Shinohara et al. (2010) investigated the effect of apple intake on fecal 
microbiota in humans. They revealed that the number of bifidobacteria, Lactobacillus and 
Streptococcus in feces increase after the intake of 2 apples/day for 2 weeks. In contrast, the 
decreased numbers of Clostridium perfringens, Enterobacteriaceae and Pseudomonas was 
observed in the same groups. Their findings indicate that apple consumption improved 
intestinal environment and apple pectin was thought to be main component underlying this 
beneficial effect. In addition, Tamura et al. (2011) found that the occupation ratio of 
Bacteroides and Clostridium cluster IV were significantly higher in fecal flora of mice given 
Japanese apricot treatment compared to the control. The authors also suggested this 
Japanese apricot fiber possesses the fecal lipid excretion effects and feces bulking effects.  
3. The kinds and nutritional status of diets and their role in the  
development of IBD 
3.1 Sugar and refined carbohydrate 
Many studies have been conducted to observe the role of sugar in the development of IBD. 
Martini and Brandes (1976) were among the earliest to reveal that intake of sugar and highly 
refined carbohydrate containing foods were higher in CD patients compared to the control. 
Mayberry et al. (1978) in UK observed the dietary breakfast on 100 CD patients and 100 
controls, matched for age and sex. No significant difference was noted for the type of foods 
taken at breakfast, except for fruit and fruit juice, which were taken more often by control. 
Nevertheless, CD patients were observed to add significantly higher amount of sugar to 
their beverages and cereals compared to control. In later studies, a higher sugar intake in CD 
patients compared to control was eventually confirmed (Mayberry et al., 1980; Silkoff et al., 
1980). Since then, numerous studies have confirmed the high level of sugar consumption 
noticed either in foods or beverages of CD patients (Jarnerot et al. 1983; Katschinski et al., 
1988; Matsui et al., 1990, Reif et al., 1997). 
Some debates have raised an issue on whether the increased sugar intake is a course or 
effect of the disease. However, the fact that increased sugar pattern has also been observed 
in new onset CD signifying that such pattern may contribute a role in the development of 
the disease. In a case controlled study, researchers used the odd ratio (OR) or relative risk 
(RR) as appropriate method for investigating the relationship between diet and disease. 
Persson et al. (1992) revealed that calculated RR of CD was increased for subjects who 
consume high amount of sucrose (>55 g/day) (RR= 2.6; 95% confidence interval (CI)= 1.4-
5.0). Reif et al. (1997) found that a high sucrose intake was associated with the increase for 
IBD, with OR= 2.85 and 5.3 against population and clinic control, respectively. In addition, 
they found that lactose consumption exhibited no effect while fructose intake was 
negatively associated with risk of IBD. Sakamoto et al. (2005) used food frequency 
questionnaire (FFQ) to compare pre-illness diet in 108 CD and 126 UC patients with the diet 
of 211 controls in Japan. They found that high consumption of sugars and sweeteners (OR= 
2.12; 95% CI= 1.08-4.17) and sweets (OR= 2.83; 95% CI= 1.38-5.83) were positively associated 
with CD risk. High intake of sweets was also observed to be positively associated with UC 
risk (OR= 2.86; 95% CI= 1.24-6.57). 
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3.2 Dietary fat 
Dietary fat is suggested to be an important factor in the development of IBD.  Hydrogenated 
fat such as margarine was found to contribute in the development of IBD. The causal 
relationship between margarine and IBD was previously proposed based on the association 
between the onsets of margarine consumption with the first report of ganulomatous ileitis 
(Geerling et al., 1999). Maconi et al. (2010) reported that moderate and high consumption on 
margarine (OR= 11.8 and OR= 21.37) was associated with UC.  
An increase of fat consumption was observed in the pre-illness period of IBD, particularly of 
UC patients (Reif et al., 1997). The kind of fat observed in the study including animal fat, 
vegetable fat, saturated fat, monounsaturated fat, polyunsaturated fat and cholesterol, in 
which high intake of animal fat and cholesterol give high OR value of 4.09 and 4.57, 
respectively (Reif et al., 1997). Geerling et al. (2000) found in their study that high intake of 
monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA) were also 
associated with the development of UC. Similarly, Sakamoto et al. (2005) revealed that the 
intake of total fat, MUFA, and n-6 fatty acids was positively associated with CD risk, 
although they failed to found association with UC. An epidemiological study from Japan 
discovered that increasing incidence of CD (between 1966 and 1985) was in parallel increase 
with daily intake of animal protein, total fat and animal fat, particularly n-6 PUFA relative 
to n-3 PUFA (Shoda et al., 1996). 
3.3 Dietary protein 
Important source of protein such as meat, cheese, milk, eggs and fish are widely taken as 
dietary protein. Patients with CD and UC as well as ulcerative proctitis disorders exhibit 
higher protein intake compared to the control subject with other gastrointestinal disorders 
(Gee et al., 1985). Tragone et al. (1995) also found higher protein intake in UC but not CD 
patients compared to the control. On the other hand, Reif et al. (1997) failed to find the 
association between protein intake and the risk of IBD in their case control study. Shoda et 
al. (1996) who conducted an epidemiologic analysis of CD in Japan showed that increased 
incidence of CD was strongly correlated with increased dietary intake of animal protein (r= 
0.908) and milk protein (r= 0.924). However, risk of CD is not correlated with fish protein (r= 
0.055) and is inversely correlated with vegetable protein (r= -0.941). The study also suggests 
that the development of CD may be contributed by high intake of animal protein and n-6 
PUFA with less n-3 PUFA. In recent study, Maconi et al. (2010) reported that high 
consumption of cheese was significantly associated (OR= 3.7; 95% CI= 1.14-12.01) with CD. 
Allergy to milk protein was also proposed to be associated with the etiology of UC. 
Truelove et al. (1961) reported in earlier time that milk exclusion from the diet of patients 
led to clinical improvement, but an exacerbation of UC was observed when milk was re-
added into the diet. Taylor and Truelove (1961) supported the theory with their discovery 
on raised circulating antibodies to cow’s milk protein. Decades later, Glassman et al. (1990) 
reported a relationship between hypersensitivity to cow’s milk during infancy and 
subsequent development of UC. Several studies investigated perinatal risk factor on the 
development of IBD found that the lack of breastfeeding is also an independent risk factor 
associated with development of CD (Koletzko et al., 1989; Thompson et al., 2000) and UC 
(Corrao et al., 1998) later in childhood. However, Koletzko et al. (1991) revealed that the 
association between breastfeeding and the increase risk of IBD remains obscure (Koletzko et 
al., 1991). Although discrepancies appear in many study, the relationship between protein 
intake and the development of IBD seems to be evidenced. 
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3.4 Other dietary components 
Many dietary components either as whole foods or micronutrients have been examined for 
their risk in the development of IBD. Persson et al. (1992) found that consumption of fast 
food at least twice a weak associated with the increased relative risk of either CD (RR= 3.4; 
95% CI= 1.3-9.3) or UC (RR= 3.9; 95% CI= 1.4-10.6). Reif et al. (1997) reported a positive 
association between retinol and the risk of IBD, while high intake of fluids, magnesium, 
vitamin C and fruits was negatively associated with the risk of IBD. In other study, a 
positive correlation was found between the intake of vitamin E (OR= 3.23; 95% CI= 1.45-717) 
and CD risk, whereas the intake of vitamin C (OR= 0.45; 95% CI= 0.21-0.99) was negatively 
related to UC risk (Sakamoto et al., 2005). A higher consumption of vitamin B6 was observed 
in UC patients compared to the control (Geerling et al., 2000). 
D’Souza et al. (2008) used the FFQ in a control case study to investigate the impact of dietary 
patterns in pediatric CD risk. They found that a characterized diet by meat, fatty food and 
dessert was positively associated with CD risk (OR= 4.7; 95% CI= 1.6-14.2). On the other hand, 
a diet characterized by fruits, vegetables, olive oil, fish, grains and nut was inversely associated 
with CD risk (OR= 0.2; 95% CI= 0.1-0.5). In other recent study, Maconi et al. (2010) evaluated 
the association between specific dietary pattern and IBD risk on adult. The dietary patterns 
were termed as refined (pasta, sweets, red and processed meat, butter and margarine), 
prudent (white meat, tuna fish, fish, eggs and potatoes) and healthy (bread, cheese, fruit and 
vegetables as well as olive oil). They observed that a “refine” pattern was associated with an 
increased risk of UC and CD. In contrast, the “prudent” diet was significantly associated with 
a decreased risk of UC and CD whiles the “healthy” pattern exhibited non significant 
association with increased risk of CD, and it was not consistently associated with UC. 
Although a meaningful conclusion cannot be drawn, these studies imply that specific dietary 
patterns has distinct role in the development of IBD either in children or adults. 
4. Mechanisms underlying the association of diet with IBD 
Diet is thought to play an important role in the development and treatment of IBD. 
However, the association between nutrition and IBD is complicated and involves several 
aspects such as nutritional support for malnourished patients, primary therapy for active 
disease and maintenance of remission, and nutrients risk factors involved in the etiology of 
IBD (Hartman et al., 2009). Malnutrition is commonly observed in patients with IBD, 
particularly CD (O’Sullivan et al., 2006; Razack and Seidner, 2007). Enteral nutrition has 
been applied as an adjunct therapy to correct or prevent malnutrition in CD patients in both 
adults and children (Dupont et al., 2008; Day et al., 2008; El-Matary, 2009). Enteral nutrition 
has also been considered to induce and maintain remission in CD (Tsujikawa et al., 2003; 
Griffiths, 2005; Smith, 2008). Nevertheless, mechanisms underlying the action of enteral 
nutrition are yet to be fully understood, although several mechanisms have been proposed 
by many researchers. These mechanisms include improvement of nutritional status (Beatti et 
al., 1994), down regulation of pro-inflammatory cytokines (de Jong et al., 2007), modification 
of gut flora (Leach, 2008), anti-inflammatory effects (Fell, 2005), promoting epithelial healing 
(Fell et al., 2000), decreased gut permeability (Guzy et al., 2009) and decreased antigenic 
load to the gut (Beatti et al., 1994). 
The association between diet and IBD is likely to be determined by major components found 
in the foods. The ability of foods containing fiber in preventing the development of IBD is 
determined by the end products resulted from the fermentation of fiber in the gut. Fiber is 
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metabolized by gastrointestinal bacteria to produce lactate, gas and short chain fatty acids 
(SCFA) such as acetate, propionate and butyrate. The most important SCFA is butyrate since 
it has anti-inflammatory effects by inhibiting NFκǃ and thus preventing transcription of 
pro-inflammatory cytokines. Butyrate is also known to reduce colonic permeability by 
promoting activation of peroxisome proliferator activated receptor Ǆ (PPAR-Ǆ) 
(Venkatraman et al., 2003). In addition, N-3 PUFA, particularly eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) have been associated with the prevention of IBD. These 
PUFA influence the inflammatory response through several mechanisms such as 
antagonizing the production of inflammatory eicosanoid mediators from arachidonic acid, 
suppress production of some inflammatory cytokines and downregulate the expression of a 
number of genes involved in inflammation (Gil, 2002). 
5. The link among diet, prebiotic and enteric microbiota mainly probiotic 
bacteria 
The human gastrointestinal tract that typically refers to stomach and intestine is colonized 
by an intricate community of microorganisms. The stomach is a home of typically 103 colony 
forming units (CFU)/g content (Gibson and Beaumont, 1996). The large intestine is the main 
colonization site of more than 500 indigenous microbial species which can reach up to 1012 
CFU/g lumen contents (Conway, 1995; Gibson and Beaumont, 1996). A wide range of 
compounds that have both positive and negative effects on gut physiology is produced 
through fermentation process by predominantly strict anaerobe gut microflora. For instance, 
short-chain fatty acids (SCFA), mainly butyrate supplies energy metabolism for the large gut 
mucosa and colonic cell growth. This SCFA is the end fermentation products of complex 
carbohydrate and protein that usually present in human diet. In contrast, H2S produced by 
sulfate-reducing bacteria is highly toxic and may induce ulcerative colitis (Gibson and 
Beaumont, 1996). From the host’s perspective, the key function of gut microflora is to 
prevent colonization by potentially harmful microorganisms. The imbalanced gut microflora 
has been linked to the development of certain disorders such as gastroenteritis, colon cancer 
and inflammatory bowel disease (Gibson and Macfarlane, 1994). The composition of gut 
microflora is considered to be fairly stable over long periods. However, numerous factors 
such as competition for nutrients, metabolic interaction among bacteria, various host 
condition and individual dietary preferences may influence alteration of the pattern (Berg, 
1981; Hill, 1986; Rowland and Tanaka, 1993). Therefore, it is of the foremost interest to 
manipulate the gut microflora composition toward an increased number of beneficial 
bacteria that provide health promising properties to the gut.  
The groups of beneficial bacteria that help maintain health and treat disease is broadly 
known as probiotic. Several definitions of probiotic have been suggested for over the years. 
Fuller (1989) defined probiotic as a live microbial food supplements which have beneficial 
effects on the host by improving its intestinal microbial balance. A probiotic bacterium 
should fulfill certain criteria to be described as useful. These include acid and bile stability, 
adherence to intestinal cells, persistence for some time in the gut, ability to produce 
antimicrobial substances, antagonism against pathogenic bacteria, ability to modulate the 
immune response, being of human origin and having generally regarded as safe (GRAS) 
status (Dunne et al., 2001). In human, probiotic has been associated with lactobacilli (e.g. 
Lactobacillus acidophilus, L. delbruekii and L. casei) and bifidobacteria (e.g. Bifidobacterium 
bifidum, B. adolescentis, B. infantis and B. longum). Other known bacteria include streptococci 
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(e.g. Streptococcus lactis and S. salivarius ss. thermophilus), nonpathogenic E. coli and 
Saccharomyces boulardii (Gibson and Roberfroid, 1995; Shanahan, 2001). 
A practical approach in increasing the number and activities of probiotic is through dietary 
supplementation, particularly with intake of the so called prebiotic. Gibson and Roberfroid 
(1995) defined a prebiotic as ‘a non digestible food ingredient that beneficially affects the 
host by selectively stimulating the growth and/or activity of one or a limited number of 
bacteria in the colon, and thus improves host health’. They revealed that food constituents 
can be categorized as prebiotic if meet the following requirements: 1) Resistant to hydrolysis 
and absorption in the upper part of gastrointestinal tract; 2) Act as selective substrate for one 
or a limited number of beneficial bacteria commensal to the colon; 3) Able to alter the 
colonic flora in favor to healthier composition; and 4) Induce luminal or systemic properties 
that are beneficial to the host health. Fructooligosaccharides (FOS), inulin, lactulose and 
galactooligosaccharides are commercially available prebiotic of proven efficacy. Inulin and 
FOS can be found in human breast milk and in food such as banana, asparagus, leeks, onion, 
garlic, wheat, chicory and tomatoes (Niness, 1999). Galactooligosaccharides (GOS), a 
mixture of oligosaccharides derived from lactose is frequently used as supplement in food 
and infant formula milk (Niness, 1999; Roberfroid, 2007). In their in vitro study, Wang and 
Gibson (1993) demonstrated that FOS and inulin are selectively fermented by most strains of 
bifidobacteria. The prebiotic effects of inulin and oligofructose in vivo have also been shown 
in many studies (Buddington et al., 1996; Kleesen et al., 1997). Moreover, the ability of these 
oligosaccharides in increasing the numbers of gut probiotic, particularly bifidobacteria has 
been shown in many human feeding studies. Breast milk is rich in human oligosaccharides 
and therefore the number of bifidobacteria in the gut microflora of breast-fed infants is 
higher than that in formula-fed infants (Gibson and Roberfroid, 1995; Harmsen et al., 
2000). The predominance of bifidobacteria in breast-fed infants is usually associated with 
lower risk of intestinal infection. However, Moro et al. (2002) reported that after 28  
days of feeding, the number of fecal bifidobacteria and lactobacilli in infant fed with a 
cow milk supplemented with FOS and GOS were significantly increased compared to the 
placebo group. 
The link between prebiotic and probiotic has been pronounced to enhance the efficacy of the 
both agents in maintaining the health of intestine. Synbiotics have been defined as ‘a 
mixture of probiotics and prebiotics that beneficially affects the host by improving the 
survival and implantation of live microbial dietary supplements in the gastrointestinal track, 
by selectively stimulating the growth and/or by activating the metabolism of one a limited 
number of health promoting bacteria, and thus improving host welfare’ (Gibson and 
Roberfroid, 1995). There are only few studies carried out to investigate the efficacy of 
synbiotics in human. Bouhnik et al. (1996) investigated the effect of symbiotic containing 
Bifidobacterium spp. and inulin fermented milk in healthy people. The authors reported that 
intake of Bifidobacterium spp. significantly increased fecal bifidobacteria, but no extra 
numbers of that particular probiotic was observed merely due to the addition of inulin. 
However, 2 weeks after trials, the volunteers who received symbiotic product had 
significantly higher number of Bifidobacterium spp. compared to those receiving probiotic 
alone. In addition, it was found that the trend whereby Bifidobacterium spp population 
decreases in the gut microflora of eldery may be reversed by the consumption of inulin 
(Kleessen et al., 1997). 
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6. The role of prebiotic and probiotic bacteria in the prevention of IBD 
The inflammatory bowel disease is of complicated etiology, wherein genetic factors, 
immunity system and environmental factors as well as the interaction among them are 
supposed to play a pivotal role in the development of these disease states. The convincing 
evidence for interaction of these factors has been exposed in experimental animal models of 
either CD or UC (Elson et al., 1995; Strober et al., 1998; Blumberg et al., 1999). The 
environment factors such as the composition and metabolic activity of the gastrointestinal 
microbiota are likely to be the most important aspect. Its relationship with the host is so 
specific, thus alteration in the balance of microorganisms might initiate the pathogenesis of 
IBD. Some of intestinal bacterial resident are considered harmful as they are involved in 
toxin production, mucosal invasion or activation of inflammatory responses. These bacteria 
include Mycobacterium paratubercolusis, Listeria monocytogenes, adherent E. coli and measles 
virus. The equilibrium between protective and harmful bacteria inside the gastrointestinal 
tract exists in healthy people. However, this equilibrium is broken in IBD people (termed as 
dysbiosis), resulting in chronic intestinal inflammation (Tamboli et al., 2004). Major 
modification in gastrointestinal microbiota in IBD patient includes increased numbers of 
coliforms, bacteroids and E.coli, as well as decreased numbers of lactic acid bacteria 
(Kennedy et al., 2000; Borruel et al., 2002). Distribution of lesions in this intestinal 
inflammation disorder is found greatest in areas with the highest numbers of luminal 
bacteria (Shanahan, 2000). The consumption of probiotic has been known to exert many 
beneficial effects. Probiotics facilitate host defense against infection through competitive 
metabolic interactions, production of antimicrobials, and inhibition of adherence or 
translocation of pathogen. In a view point of IBD, Shanahan (2000) revealed that anti-
inflammatory effects of probiotic require signal with gastrointestinal epithelium and 
mucosal regulatory T cells or dendritic cells.  
Many studies revealed that oral administration of probiotic in tandem with prebiotic 
promote the prevention of IBD. Prebiotic is growth substrates specifically directed toward 
indigenous beneficial bacteria in colon, thus amplify the probiotic effects in preventing IBD. 
Although there is no recommended daily dose of prebiotic, but Roberfroid et al. (1998) 
suggested that a minimum daily dose of 4 g of inulin or FOS would be sufficient to increase 
the numbers of bifidobacteria in the intestine. In people with IBD, intake of prebiotic is 
required to prevent the disease recurrence, since prebiotic served as substrate for probiotic 
to produce SCFAs particularly butyrate that exert protective effects to the gut. For instances, 
Videla et al. (1994) reported that prebiotic inulin increases colonic butyrate and reduces 
inflammation and disease severity in animal models of colitis. Germinated barley foodstuff 
(GBF) rich in fiber also alleviate the symptomatology in both animal models of UC and 
patients with UC (Bamba et al., 2002). GFB is efficiently increases luminal butyrate 
production by stimulating the growth of protective bacteria (Kanauchi et al., 2002, Kanauchi 
et al., 2003). Therefore, the prebiotic and probiotic are likely work synergistically in the 
prevention of IBD. 
7. The role of prebiotic and probiotic in the management and treatment of IBD 
Prebiotic and probiotic have been widely involved in the management and treatment of IBD. 
Many studies on the use of prebiotic in the management of IBD are presented in Table 1. 
Fernandez-Banares et al. (1999) shown that a diet with Plantago ovate seeds was as effective 
as mesalazine in maintenance of remission in inactive UC patients in a randomized 
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controlled trial. Oral administration of GBF has been known to reduce clinical activity and 
prolonged remission time in UC patients (Kanauchi et al., 2002; Kanauchi et al., 2003; Hanai 
et al., 2004). In a recent study, Casellas et al. (2007) investigated the effect of oligofructose-
enriched inulin in patients with active UC. They revealed that at day 7, an early significant 
reduction of fecal calprotectin was observed in patients who had taken oligofructose-
enriched inulin, but not in placebo group. Fecal calprotectin has been used as an objective 
and quantitative marker of intestinal inflammation and its levels correlated significantly 
with histologic and endoscopic assessment of disease activity in UC (Roseth et al., 1997; 
Konikoff and Denson, 2006). Inulin has also been assayed in a placebo controlled clinical 
trial in patients with relapsing pouchitis (Welters et al., 2002). Dietary supplementation with 
inulin (24 g/day for 3 weeks) resulted in an increase of butyrate level, lower in pH, 
decreased numbers of Bacteroides fragilis and diminished level of secondary bile acids in 
feces. The authors further revealed that inulin was associated with reduction of endoscopic 
and histological scores of mucosal inflammation in the ileal reservoir. Nevertheless, more 
clinical trials are required to further validate the efficacy of dietary fiber as prebiotic in the 
management of IBD. 
 
Prebiotic Disease 
Number of 
patients 
Duration Outcome Results Reference 
Inulin (24 g/day) Pouchitis 20 adults 2.2 months 
Reduction of 
inflammation of the 
mucosa of the ileal 
reservoir. 
Welters et al. 
(2002) 
Plantago ovata seed UC 105 adults 12 months 
Maintain remission as 
effective as 
mesalamine, Increased 
in fecal butyrate. 
Fernandez-
Banarez et al. 
(1999) 
Synbiotic 2000 * CD 30 adults 24 months 
Fail to prevent 
postoperative 
recurrence. 
Chermesh et 
al. (2007) 
Synergy 1 (inulin 
and oligofructose) 6 
g/day and 
Bifidobacterium 
longum 
UC 18 adults 1 months 
Reduction of ǃ-
defensins 2, 3, and 4, 
TNFǂ and Interleukin 
1ǂ. 
Furrie et al. 
(2005) 
Germinated barley 
foodstuff (30 
g/day) 
UC 10 adults 1 months 
Reduction of clinical 
activity index scores 
and increase in stool 
butyrate 
concentrations. 
Mitsuyama et 
al. (1998) 
*: Synbiotic 2000 is combination of probiotic (Lactobacillus raffinolactis, L. paracasei, L. plantarum, 
Pediococcus pentosaceus) and prebiotic (2.5 g ǃ-glucan, 2.5 g inulin, 2.5 g pectin and 2.5 g resistant starch). 
Table 1. Studies of probiotics in the management of inflammatory bowel disease (IBD) 
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Many clinical studies have confirmed the efficacy of probiotic in the management and 
treatment of IBD (Table 2). In 1999, Venturi et al. reported the efficacy of VSL#3 (at 6 g/day) 
as maintenance treatment in patients with ulcerative colitis in remission and intolerance to 
5-aminosalicylic acid (5-ASA). They observed that 75% of patients given VSL#3 remained in 
remission without any side effects throughout the 12 months period. VSL#3 is comprised of 
lyophilized viable cell of 4 strains of Lactobacillus (L. casei, L. achidophilus, L. plantarum and L. 
bulgaricus), 3 strains of Bifidobacterium (B. longum, B. breve and B. infantis) and 1 strain of 
Streptococcus thermophilus. In addition, the mixture of probiotic is found to be able to 
upregulate the intestinal mucosal alkaline sphingomyelinase and reduce the inflammation 
risk in UC patients (Soo et al., 2008). A non-patoghenic E. coli, Nissle 1917, also exhibits 
similar efficacy with mesalazine (the standard treatment) in the maintenance of UC 
(Rembacken et al., 1999; Kruis et al., 2004). In other study, the ability of Saccharomyces 
boulardii to induce the remission in 71% of patients with mild to moderate UC was reported 
(Guslandi et al., 2003). 
There are only few controlled clinical studies using probiotic in CD and the results were 
somehow inconsistent. Malin et al. (1996) reported that intake of Lactobacillus rhamnosus 
GG (2×1010 CFU/day, for 10 days) in pediatric CD stimulates the gut IgA levels, which 
could promote the gut immune response. Furthermore, using the same probiotic strain 
and dose, Gupta et al. (2000) reported an improved clinical scores and intestinal 
permeability in an open-labeled pilot study with four children with CD. In contrast, 
Prantera et al. (2002) reported the ineffectivity of Lactobacillus rhamnosus GG in preventing 
post operative disease recurrence or reducing severity of recurrent lesion in patients with 
CD. In addition, Lactobacillus johnsonii La1 was also unable to prevent endoscopic 
recurrence in the 12 week period following ileo-caecal resection (Van Gossum et al., 2005). 
Chermesh et al. (2007) showed that post operative recurrence of CD patients was not 
prevented by Synbiotic 2000, a combination of 4 probiotic lactic acid bacteria (Lactobacillus 
raffinolactis, L. paracasei, L. plantarum, Pediococcus pentosaceus) and 4 prebiotic fermentable 
fibers (beta-glucans, inulin, pectin, resistant starch). However, combination treatment of 
antibiotic rifaximin and probiotic VSL#3 resulted in a significantly lower incidence of 
severe endoscopic recurrence compared with mesalazine treatment (Campieri et al., 2000). 
Combination of VSL#3 and Saccharomyces boulardii was also observed to give a therapeutic 
effect in patients with CD. 
Gionchetti et al. (2000) investigated the efficacy of VSL#3 (at 6 g/day) oral administration in 
the maintenance of remission in chronic pouchities in the double blind controlled study. 
They found that 15% patients in the VSL#3 group had relapses, compared with 100% 
patients in the placebo group (P<0.001) over a nine month trial period. The mechanism of 
VSL#3’s impressive effect has not been established. However, Gionchetti et al. (1999) have 
previously found that the intake of VSL#3 increases faecal concentration of lactobacilli, 
bifidobacteria and streptococci, as well as increases tissue levels of IL-10 in patients with 
chronic pouchitis. Since the efficacy disappears after stopping therapy, the efficacy of VSL#3 
therapy was thought to be due to the ongoing presence of these factors. In contrast, Kuisma 
et al. (2003) showed that Lactobacillus rhamnosus GG was ineffective to prevent relapses in 
patients with chronic pouchitis in a placebo controlled trial. In an open-labeled study, 
combined Lactobacillus rhamnosus LGG and prebiotic fructooligosaccharide, when 
administered as adjuvant to antibiotic therapy, induce remission in patients with pouchitis 
(Friedman and Goerge, 2000). 
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Probiotic Strains 
and dose 
Disease 
Patients number and 
condition 
Duration Outcome Results Reference 
VSL#3 * 
UC, in 
remission 
20 adults (12 male, 8 
female), intolerance to 
5-ASA 
12 months 
75% patients remained in 
remission during study period, 
no side effects 
Venturi et al. 
(1999) 
Eschericia coli Nissle 
1917 
(1×1011cfu/day) 
UC, active 
116 adult adults, treated 
with prednisolon + 
gentamicin plus either 
probiotic of mesalazine 
3 months 
Prebiotic induce remission as 
effective as mesalazine 
(standard treatment) 
Rembacken et 
al. (1999) 
Eschericia coli Nissle 
1917 
(1×1011 cfu/day) 
UC, in 
remission 
116 adult adults 12 months 
Prebiotic shown equivalent 
efficacy with mesalazine in the 
maintenance of remission 
Rembacken et 
al. (1999) 
VSL#3 UC, active 30 adults 6 weeks 
VSL#3 resulted in combined 
induction of 
remission/response rate of 
70%, with no adverse effects 
Bibiloni et al. 
(2005) 
Saccharomyces 
boulardii 
UC, in 
remission 
25 adults, unsuitable for 
steroid therapy 
1 months 
71%  patients remained in 
remission 
Guslandi et al. 
(2003) 
Yakult ** 
(1×1010 cfu/day) 
UC 
21 adults (11 male, 10 
female) 
12 months 
73% patients treated with 
probiotic remained in 
remission, while only 10% 
placebo 
Ishikawa et al. 
(2003) 
Saccharomyces 
boulardii 
CD, in 
remission 
32 adults (20 male, 12 
female) 
6 months 
Probiotic plus mesalamine 
reduced relapsing incindence 
compared to mesalamine alone 
Guslandi et al. 
(2000) 
Lactobacillus 
rhamnosus GG 
(2×1010 cfu/day) 
CD 4 children 6 months 
Improve gut barrier function, 
pediatric crohn’s disease 
activity index (PCDAI) were 
73% lower than baseline 
Gupta et al. 
(2000) 
Lactobacillus GG 
(1×1010 cfu/day) 
CD 14 adults 10 days 
Increase the IgA immune 
response, thus promote the gut 
immunological barrier 
Malin et al. 
(1996) 
VSL#3 
(1.8×1012 cfu/day) 
Pouchitis 40 adults 9 months 
Reduced risk of relapse 
recurring, only 15% patient in 
probiotic group relapsed 
compared with 100% in placebo 
group 
Gionchetti et al. 
(2000) 
Cultura *** 
(5×1010 cfu/day) 
Pouchits 10 adults 1 months 
50% endoscopic improvement, 
but no  
histological improvement 
Laake et al. 
(2003) 
VSL#3 
(1.8×1012 cfu/day) 
Pouchitis 36 adults 12 months 
Induced remission in 85% 
patients 
Mimura et al. 
(2004) 
*: VSL#3 (VSL Pharmaceuticals Inc., Fort Lauderdale, Florida, USA) contain 4 strains of  
Lactobacillus (L. casei, L. achidophilus, L. plantarum and L. bulgaricus), 3 strains of  
Bifidobacterium (B. longum, B. breve and B. infantis) and 1 strain of Streptococcus  
thermophilus.   
**: Yakult (Yakult Honsha Co. Ltd., Tokyo, Japan) contain Bifidobacterium breve, B. bifidum and 
Lactobacillus acidhophilus.  
***: Cultura® (TINE Dairies BA, Oslo, Norway) contain 1×1010 live Lactobacillus acidophilus and 
Bifidobacterium lactis per 100 g. 
Table 2. Studies of probiotics in the management of inflammatory bowel disease (IBD) 
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8. The underlying mechanisms of the protective effects of probiotic bacteria 
Many studies have been addressed to disentangle the mechanisms on how probiotic bacteria 
exert their beneficial effects on human health. Although not entirely understood, several 
mechanisms underlying the useful action of probiotic have been proposed by researchers. 
The mechanisms include production of inhibitory substances, competitive exclusion of 
microbial adherence or translocation, modulation of immune response and reinforcement of 
barrier function. These functions are likely interrelated in supporting the protective effect of 
probiotic. Furthermore, it should be emphasized that the action of probiotic is species and 
strains specific, thus, appropriate choice of microorganism is of particular attention to 
improve the efficacy of probiotic treatment. 
8.1 Production of inhibitory substances 
Probiotic bacteria produce various substances that perform as inhibitory agents to 
pathogenic bacteria. The inhibitory agents such as organic acids, hydrogen peroxide and 
bacteriocins are typically produced by probiotic. These compounds may reduce the number 
of viable cells as well as inhibit bacterial metabolism or toxin production (Rolfe, 2000). 
Several strains of Lactobacilli produce acetic, lactic and propionic acid that decrease the local 
pH thus inhibit the growth of many Gram-negative pathogenic bacteria. Some strains of 
Lactobacillus inhibit the growth of Salmonella enterotica merely by the production of lactic 
acid (Makras et al., 2006). The 2-component lantibiotics (lanthionine and methyllanthionine) 
are small microbial peptide bacteriocins produced by Gram positive bacteria such as 
Lactococcus lactis (Lawton et al., 2007). At nanomolar concentration, these peptides actively 
inhibit multidrug resistant pathogens by targeting the lipid II component of the bacterial cell 
wall (Morgan et al., 2005). Lactobacilli are also known to produce non-lanthione containing 
bacteriocins. A large group of bacteriocins with highly divergence sequences are produced 
by Lactobacillus strains including L. plantarum, L. sakei, L. acidophilus NCFM, and L. 
johnsonii NCC 533 (Makarova et al., 2006; Chaillou et al., 2005; Altermann et al., 2005; 
Pridmore et al., 2004). In addition, Collado et al. (2005) reported that several strains of 
human fecal Bifidobacteria produce bacteriocin like compounds that exert toxicity to both 
Gram-positive and negative bacteria. 
8.2 Competitive exclusion of microbial adhesion or translocation 
The adhesive properties of probiotic bacteria on epithelial cells enable the competitive 
inhibition of bacterial adhesion site, thus hampering colonization of pathogenic bacteria (He 
et al., 2001; Lee and Puong, 2002; Boudeau et al., 2003). Some probiotic have the ability to 
block the intestinal mucosal receptor, thus prevent adhesion of pathogenic bacteria. Several 
strains of Lactobacilli and Bifidobacteria are able to compete with many pathogenic bacteria 
such as Bacteroides vulgates, Enterobacter aerogene, Listeria monocytogenes, 
Staphylococcus aureus, Salmonella enterica, enterotoxigenic E. coli and enteropathogenic  
E. coli for intestinal epithelial cell binding (Collado et al., 2007; Candela et al., 2005; Roselli  
et al., 2006; Sherman et al., 2005). Displacement of pathogenic bacteria can also occur even  
if the pathogen have attached to intestinal epithelial cells prior to prebiotic treatment 
(Collado et al., 2007; Candela et al., 2005). Nevertheless, specific strains of probiotic or  
its combinations are required to inhibit or displace specific strains of pathogen (Collado et 
al., 2007). 
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8.3 Modulation of immune response 
Probiotic bacteria play a key role in stimulating the immunity by increasing 
immunoglobulin A (IgA) production (Gewirtz et al., 2002). Bakker-Zierikzee et al. (2006) 
reported that fecal sIgA levels increase in infants fed with Bifidobacterium animalis 
enriched formula, and suggested that the use of probiotic may reinforce innate function. 
Interestingly, beside resulting in increased levels of fecal sIgA, spleen cells of mice treated 
with non viable LGG exhibited enhanced secretion of IL-6 which stimulate IgA antibody 
response at the mucosal surface (He et al., 2005). Moreover, probiotic protects the intestine 
from pathogen induced injury by modulating the balance of pro and anti-inflammatory 
cytokine production. Probiotic increase anti-inflammatory interleukin (IL)-10 and inhibited 
generation of inflammatory Th1 cells as well as decreases pro-inflammatory IL-12 (Hart et 
al., 2004). For instances, VSL#3 induces the production of IL-10 in human and murine 
dendritic cells (Drakes et al., 2004; Hart et al., 2004). Di Giancinto et al. (2005) reported that 
VSL#3 also stimulate IL-10 production in chemically induced IBD.  
The ability of probiotic in suppressing pro-inflammatory cytokine production has been 
accounted for their efficacy in the treatment of IBD. Pena et al. (2005) said that LGG inhibit 
lipopolisaccharide (LPP) and Helicobacter pylori-stimulated tumor necrosis factor (TNF) 
production by murine macrophage. The authors further explained that substances derived 
from LGG decrease TNF production in macrophages in LGG conditioned cell culture media. 
In addition, Lactobacillus casei strain Shirota (LcS) inhibits the regulation of LPS-induced 
IL-6 and the production of IFN-Ǆ by peripheral blood mononuclear cells isolated from 
normal and chronic colitis mice (Matsumoto et al., 2005). In colonic biopsies of inflamed 
mucosa from UC patients, Bifidobacterium longum was found to reduce the secretion of 
pro-inflammatory TNF-ǂ and IL-8 (Bai et al., 2006). Moreover, Sturm et al. (2005) reported 
that E. coli Nissle 1917 inhibits peripheral bold T-cell cycle progression and expansion, 
increase IL-10 and decrease the liberation of TNF, IFN-Ǆ and IL-2. 
8.4 Reinforcement of barrier function 
The defensive mechanisms of the intestinal epithelium are manifested by the intestinal 
barrier function which requires effective tight junctional complexes between the epithelial 
cells. The intestinal disintegrates are likely occur when the tight junctional structure or its 
function are disrupted, resulting in an increased ability of pathogenic bacteria to attach to 
the gut mucosa. Many studies revealed that the processes involved in mucosal barrier 
formation are possibly modulated by probiotic, as well as shown the function of probiotic in 
upregulating expression of defensins, mucins or other proteins associated with tight 
junction such as claudins and occludins. Therefore, the ability of probiotic in inducing 
barrier formation is considered as an important mode underlying their efficacy in the 
prevention and treatment of IBD. Zyrek et al. (2007) have shown that in vitro E.coli Nissle 
1917 restored the disrupted epithelial barrier in the polarized T84 cell infected by 
enteropthogenic E. coli strains E2348/68. They found that E.coli Nissle 1917 increases 
expression and distribution of zonula occludens-2 (ZO-2) protein and of distinct protein 
kinase C isotopes to the cell surfaces to exert that protective function. Probiotic VSL#3 
increased mucin gene expression and excretion in intestinal epithelial cells (Caballero-
Franco et al., 2007). VSL#3 and Lactobacillus fermentum maintain the intestinal barrier 
function by upregulating the human ǃ-defensin-2 (Schlee et al., 2008). ǃ-defensin is an 
inducible antimicrobial peptide synthesized by the intestinal epithelial cells to prevent 
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bacterial adherence and invasion (Wehkamp et al.,2004). In rats with ethanol induced colitis, 
LGG increases the production of Muc6 and basal mucosal PGE2, resulting in an increased 
thickness of the mucosal mucus layer of the stomach (Lam et al., 2007). In addition to 
bacteria, Garcia Vilela et al. (2008) reported that yeast Saccharomyces boulardii induces the 
improvement but not normalization in leaky gut of CD patients. 
The prevention of cytokine-induced epithelial damage by enhancing intestinal epithelial cell 
survival is another mechanism contributing the clinical efficacy of probiotic. Probiotic 
exhibit cytoprotective function by reducing intestinal epithelial apoptosis (Yan and Polk., 
2002; Lin et al., 2008). Apoptosis is a major factor in the colonic inflammatory response and 
the pathogenesis of IBD (Sartor, 2002). LGG is found to prevents cytokine-induced apoptosis 
either in human or mouse intestinal epithelial cells by activating antiapoptotic Akt in a 
phosphatidylinositol-3-kinase (PI3K)-dependent manner, as well as preventing proapoptotic 
p38/MAPK activation (Yan and Polk, 2002).  
9. Conclusion 
Inflammatory bowel disease is a complex disorder in which both genetic and environmental 
factors involved in the pathogenesis of IBD. Most pivotal etiological factor for IBD is the 
alteration of gastrointestinal microbial flora to a larger proportion of harmful rather than 
beneficial bacteria. The alteration is likely to be strongly affected by the type of diet intake. 
Fibers containing foods are considered as good substances that may enhance the number of 
beneficial bacteria in the gut, thus maintaining the health of the gut. The end products of 
fiber fermentation by bacteria in the gut exert many beneficial impacts on either bacteria or 
host. For instance, short chain fatty acids, particularly butyrate that provides energy to the 
host and involved in regulating the anti-inflammatory constituents, was found to protect the 
gut. Efforts to manipulate the bacterial composition of the gut toward a more salutary 
regiment are of emerging interest today. The most prominent effort is by introducing 
probiotic (such as lactobacilli and bifidobacteria) and prebiotic (such as inulin and 
fructooligosaccharide) into the intestine. Probiotics and prebiotics have been used as 
altervative to current drug treatment in large number of studies of gastrointestinal disorder, 
particularly IBD. Several evidences support the efficacy of probiotic and prebiotic in the 
prevention and treatment of UC, CD or pouchitis. However, many trials have given 
conflicting results; thus large clinical trials using standardized methodology are required to 
reconfirm the evidences. In addition, more research should be better focused on 
mechanisms underlying the protective effects of probiotic and prebiotic; thus can be 
translated into meaningful clinical trial outcome. 
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